Portal de Periódicos da CAPES

Mometasone Furoate Ointment 0.1% vs. Hydrocortisone Ointment 1.0% in Psoriasis

1989; Wiley; Volume: 28; Issue: 5 Linguagem: Inglês

10.1111/j.1365-4362.1989.tb01361.x

1365-4632

Harry Irving Katz, Steven E. Prawer, Mary Jane Watson, Thomas A. Scull, Edwin A. Peets,

Autoimmune Bullous Skin Diseases

International Journal of DermatologyVolume 28, Issue 5 p. 342-345 Mometasone Furoate Ointment 0.1% vs. Hydrocortisone Ointment 1.0% in Psoriasis Atrophogenic Potential Harry I. Katz M.D., Harry I. Katz M.D. From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseySearch for more papers by this authorSteven E. Prawer M.D., Steven E. Prawer M.D. From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseySearch for more papers by this authorMary Jane Watson Pharm.D., Mary Jane Watson Pharm.D. From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseySearch for more papers by this authorThomas A. Scull, Thomas A. Scull From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseySearch for more papers by this authorEdwin A. Peets Ph.D., Corresponding Author Edwin A. Peets Ph.D. From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseyAddress for correspondence: Edwin A. Peets, Ph.D., Clinical Research, Schering Corporation, 2000 Galloping Hill Road, Kenilworth, NJ 07033.Search for more papers by this author Harry I. Katz M.D., Harry I. Katz M.D. From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseySearch for more papers by this authorSteven E. Prawer M.D., Steven E. Prawer M.D. From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseySearch for more papers by this authorMary Jane Watson Pharm.D., Mary Jane Watson Pharm.D. From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseySearch for more papers by this authorThomas A. Scull, Thomas A. Scull From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseySearch for more papers by this authorEdwin A. Peets Ph.D., Corresponding Author Edwin A. Peets Ph.D. From the Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, Minnesota, the Minnesota Clinical Study Center, Fridley, Minnesota, and the Schering Corporation, Kenilworth, New JerseyAddress for correspondence: Edwin A. Peets, Ph.D., Clinical Research, Schering Corporation, 2000 Galloping Hill Road, Kenilworth, NJ 07033.Search for more papers by this author First published: June 1989 https://doi.org/10.1111/j.1365-4362.1989.tb01361.xCitations: 20 Sponsored by a grant from the Schering Corporation. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Cornell RC, Stought RB. The use of topical steroids in psoriasis. Dermatol Clin. 1984; 2: 397– 409. 2 Dykes PF, Marks R. An appraisal of the methods used in the assessment of atrophy from topical corticosteroids. Br J Dermatol. 1979; 101: 599– 609. 3 Lehmann P, Zheng P, Lavker RM, et al. Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol. 1983; 81: 169– 176. 4 Sneddon IB. Atrophy of the skin: the clinical problems. Br J Dermatol. 1976; 94 (suppl 12): 121– 123. 5 Frosch PJ. Methods for quantifying the cutaneous adverse effects of topical corticosteroids. In: AM Kligman, JJ Leyden, eds. Safety and efficacy of topical drugs and cosmetics. Philadelphia : Grune & Stratton, 1982: 119– 134. 6 Black MM, Platt NE, Mugglestone CJ. A study of potential skin atrophy following topical application of weak corticosteroids. Curr Med Res Opin. 1981; 7 (7): 463– 468. 7 Lavker RM, Schechter NM, Lazarus GS. Effects of topical corticosteroids on human dermis. Br J Dermatol. 1986; 115 (suppl 31): 101– 107. 8 Katz HI, Prawer SE, Mooney JJ, et al. Preatrophy: an early covert sign of thinning of the skin. J Am Acad Dermatol. (in press). 9 Cornell RC. Atrophogenic potential of alclometasone dipropionate ointment 0.05% vs hydrocortisone ointment 1%. Curr Ther Res. 1986; 39: 260– 268. 10 Therapeutic Agents of Special Interest to Dermatologists. S Maddin, ed. Current dermatologic therapy. Philadelphia : W.B. Saunders Co., 1982: 514. 11 Smith CC. Urinary excretion of 17-ketosteroids and 17-hydroxycorticosteroids after inunction of hydrocortisone ointment. J Invest Dermatol. 1955; 25: 67– 69. 12 Bressinck R, Williams J, Peets EA. Effect of mometasone furoate ointment 0.1% and hydrocortisone ointment 1% on adrenocortical function in psoriasis patients. Today's Therapeutic Trends. 1988; 5(4): 25– 35. Citing Literature Volume28, Issue5June 1989Pages 342-345 ReferencesRelatedInformation